The UCSD CFAR has been in existence since 1994. It serves investigators at UCSD and three participating institutions: the Veterans Medical Research Foundation of the San Diego VA Healthcare System, the Salk Institute and the La Jolla Institute for Allergy and Immunology. The CFAR has significantly enhanced HIV/AIDS activities at the participating institutions and the San Diego Community in general by 1) encouraging young faculty and investigators new to mV/AIDS research through Developmental Grant Awards. 2) Providing expert advice and services in a number of specialized research areas through the CFAR Core Program and 3) fostering research interactions and community wide education through its programs in mentoring, training, education and outreach. The proposed CFAR consists of six cores: Developmental, Molecular Biology, Flow Cytometry (including the Immune Response sub-core), Genomics, Virology and Clinical Investigation. These cores are directly responsible to the Directors and the Executive Committee. Center membership is composed of the 180 faculty spanning 20 Departments in UCSD and the Center's participating institutions. The management of the Center is assisted by the Executive Committee, comprised of six investigators from UCSD and our collaborating institutions who are not directly funded by the CFAR: Bruce Torbett (The Scripps Research Institute), Ned Landau (Infectious Diseases, The Salk Institute), Carl Ware (The La Jolla Institute for Allergy and Immunology, LJIAI), Igor Grant (UCSD, HIV Neurobehavioral Research Center), Allen McCutchan (UCSD, NeuroAIDS), Sam Bozzette (UCSD, Health Services) and Josh Refer (Infectious Diseases, VA Medical Center, VAMC). In addition, our External Advisory Committee meets annually to monitor the scientific direction and growth of the CFAR as well as reviewing and evaluating individual core performance. The Committee offers feedback on our performance in achieving our milestones and aids in the formulation of new directions. The EAC is comprised of a group of internationally renowned AIDS investigators: Ron Desrosiers, David Ho, King Holmes, Eric Hunter, Gary Nabel and Mario Stevenson. Both committees provide us with the opportunity to draw upon and integrate their knowledge and advice, providing objective management decisions and helping guide the Center in new, productive directions. In the past year, several significant improvements have been incorporated into the program. These include a more formal and transparent administrative process of review and decision making, an enhanced Developmental Core, restructuring the CFAR membership into Program Areas to foster more collaboration and interaction and increased efforts in community education and outreach. These improvements are already enhancing the community wide HIV/AIDS activities by our already highly productive and useful CFAR.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI036214-17
Application #
7872818
Study Section
Special Emphasis Panel (ZAI1-EC-A (J1))
Program Officer
Namkung, Ann S
Project Start
1994-04-01
Project End
2012-05-31
Budget Start
2010-06-01
Budget End
2011-05-31
Support Year
17
Fiscal Year
2010
Total Cost
$2,786,561
Indirect Cost
Name
University of California San Diego
Department
Pathology
Type
Schools of Medicine
DUNS #
804355790
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Namazi, Golnaz; Fajnzylber, Jesse M; Aga, Evgenia et al. (2018) The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies. J Infect Dis 218:1954-1963
Lada, Steven M; Huang, Karissa; VanBelzen, D Jake et al. (2018) Quantitation of Integrated HIV Provirus by Pulsed-Field Gel Electrophoresis and Droplet Digital PCR. J Clin Microbiol 56:
Cepeda, Javier A; Eritsyan, Ksenia; Vickerman, Peter et al. (2018) Potential impact of implementing and scaling up harm reduction and antiretroviral therapy on HIV prevalence and mortality and overdose deaths among people who inject drugs in two Russian cities: a modelling study. Lancet HIV 5:e578-e587
Skaathun, Britt; Voisin, Dexter R; Cornwell, Benjamin et al. (2018) A Longitudinal Examination of Factors Associated with Network Bridging Among YMSM: Implications for HIV Prevention. AIDS Behav :
Stone, Jack; Fraser, Hannah; Lim, Aaron G et al. (2018) Incarceration history and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis. Lancet Infect Dis 18:1397-1409
Huang, Mia L; Michalak, Austen L; Fisher, Christopher J et al. (2018) Small Molecule Antagonist of Cell Surface Glycosaminoglycans Restricts Mouse Embryonic Stem Cells in a Pluripotent State. Stem Cells 36:45-54
Prakash, Katya; Gianella, Sara; Dubé, Karine et al. (2018) Willingness to participate in HIV research at the end of life (EOL). PLoS One 13:e0199670
Fraser, Hannah; Mukandavire, Christinah; Martin, Natasha K et al. (2018) Modelling the impact of a national scale-up of interventions on hepatitis C virus transmission among people who inject drugs in Scotland. Addiction 113:2118-2131
Macal, Monica; Jo, Yeara; Dallari, Simone et al. (2018) Self-Renewal and Toll-like Receptor Signaling Sustain Exhausted Plasmacytoid Dendritic Cells during Chronic Viral Infection. Immunity 48:730-744.e5
Papasavvas, Emmanouil; Lada, Steven M; Joseph, Jocelin et al. (2018) Analytical ART interruption does not irreversibly change pre-interruption levels of cellular HIV. AIDS :

Showing the most recent 10 out of 921 publications